NCT Number: NCT00476307
Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People 18 Years Old or Above
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® containing the influenza strains recommended for the 2007-2008 season.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
GSK Investigational Site, Dresden, Saxony, Germany
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Healthy male or female aged 18 years or above;
- Non-childbearing or using adequate contraception;
- Written informed consent obtained from the subject.
Exclusion criteria
Subjects must not:
- Participate in a trial or using non-registered product;
- Use immunosuppressants, blood products, or another influenza vaccine during study;
- Have virologically confirmed influenza within 1 year;
- Have allergic or acute disease;
- Have unstabilized serious chronic disease;
- Be a lactating female.
Treatment and study plan
Primary outcomes
-
Immune response 21 days post vaccination
Secondary outcomes
-
Safety: solicited local and general symptoms, unsolicited symptoms, serious adverse events
Sponsors and collaborators
Lead sponsor
GlaxoSmithKline
Industry
Registry information
Official study title
A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People Aged 18 Years or Above
Important dates
- Study start
- 2007
- Study completion
- 2007
- First posted
- May 22, 2007
- Registry last updated
- Nov 4, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
NCT04794829
COVID-19, Coronaviridae Infections
Bethesda, Maryland, United States
View Trial DetailsPhase I/II Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose)
NCT07737106
Infections, Influenza
Bayan Nur, Inner Mongolia, China
View Trial DetailsImmunogenicity of Influenza Vaccinations
NCT06518577
Infections, Influenza
Phoenix, Arizona, United States
View Trial DetailsAssess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59
NCT06560151
Infections, Influenza
Atlanta, Georgia, United States
View Trial Details